Highland Capital Management (Texas)’s Neurocrine Biosciences NBIX Stock Holding History

Highland Capital Management (Texas)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-37,110	Closed	-$1.71M	–	331
2017 Q2	$1.71M	Sell	37,110 -25,890	-41%	-$1.26M	0.07%	149
2017 Q1	$2.73M	Buy	+63,000	New	+$2.7M	0.14%	133
2016 Q4	–	Sell	-92,257	Closed	-$4.67M	–	322
2016 Q3	$4.67M	Buy	92,257 +15,700	+21%	+$782K	0.14%	131
2016 Q2	$3.48M	Sell	76,557 -58,443	-43%	-$2.69M	0.14%	133
2016 Q1	$5.34M	Buy	135,000 +98,502	+270%	+$3.91M	0.24%	110
2015 Q4	$2.06M	Sell	36,498 -134,902	-79%	-$6.86M	0.07%	168
2015 Q3	$6.82M	Sell	171,400 -34,600	-17%	-$1.67M	0.2%	126
2015 Q2	$9.84M	Buy	206,000 +76,000	+58%	+$3.22M	0.2%	119
2015 Q1	$5.16M	Buy	+130,000	New	+$4.65M	0.11%	149
2014 Q2	–	Sell	-80,000	Closed	-$1.29M	–	293
2014 Q1	$1.29M	Buy	+80,000	New	+$1.37M	0.05%	146

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highland Capital Management (Texas)'s NBIX Position: Q3 2017 in Review

Highland Capital Management (Texas) sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 37,110 shares — an estimated $1.71M sold.

Highland Capital Management (Texas) first reported a position in NBIX in Q1 2014 and held it in 10 quarters. The position peaked at $9.84M in Q2 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

Highland Capital Management (Texas) reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
Highland Capital Management (Texas) sold 37,110 Neurocrine Biosciences shares in Q3 2017, an estimated $1.71M.
Highland Capital Management (Texas) first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 10 quarters.
Highland Capital Management (Texas)'s Neurocrine Biosciences position peaked at $9.84M in Q2 2015.
223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Highland Capital Management (Texas)'s 13F filing for Q3 2017, filed 14 Nov 2017.